Coronary Artery Disease
Conditions
Keywords
Ezetimibe, Plant sterol, Hydroxymethylglutaryl coenzyme A Reductase Inhibitors, Coronary artery disease, LDL-cholesterol
Brief summary
The purpose of this study is to determine the effect of plant sterols associated with ezetimibe in LDL-cholesterol levels in coronary patients previously on statin therapy
Detailed description
Background: Consumption of food products enriched with plant sterols and treatment with ezetimibe both reduce cholesterol absorption in the intestine by different mechanisms and effectively reduce LDL cholesterol (LDL-c) plasma levels. Although, the associated usage of ezetimibe to plants sterols in coronary patients not reaching recommended lipid levels despite the use of statins has not yet been demonstrated. Objectives: Evaluate if ezetimibe 10mg associated to plant sterols spread enriched with 2g of plant sterols in coronary patients not reaching recommended lipid levels despite the use of statins is able to reduce cholesterol levels after 6 week treatment. Methods: Prospective, open-label study with both male and female patients with stable coronary disease and LDL \> 70mg/dL. Patients will be randomized for the following 6 week treatment: control group (CT) no additional statin therapy, ezetimibe group (EZ) 10 mg/day ezetimibe, plant sterol group (PS) spread enriched with 2g of plant sterols or ezetimibe+plant sterols group (EZ+PS) 10mg/day EZ + 2g PS. Anthropometric evaluations and laboratory exams (blood glucose test, total cholesterol, LDL-c, HDL-c, triglycerides, and C-Reactive Protein) will be performed in all groups at baseline and after the sixth week intervention.
Interventions
OTHEREzetimibe + plant sterols
The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
DRUGEzetimibe
The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
DIETARY_SUPPLEMENTPlant sterols
The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
Sponsors
Jose Rocha Faria Neto
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with previous myocardial infarction, stroke or coronary angiography demonstrating significant coronary disease. * Subjects under statin treatment with a fixed dosage for the previous three months before randomization, and did not reached LDL less than 70mg/dl.
Exclusion criteria
* Subjects already taking ezetimibe and/or plant sterols * Younger than 18 years * Presence of any contraindication to statin * Pregnant women or breast-feeding women or * Patients with previous history of statin hypersensibility
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease of LDL cholesterol levels due to plant sterols associated with ezetimibe. | 6 weeks | The primary end-point was the LDL cholesterol levels change after the plant sterols associated with ezetimibe from baseline up to 6 week treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Any change of non-LDL-cholesterol, total cholesterol, high-density lipoprotein (HDL), very-low-density lipoprotein (VLDL), triglycerides levels, and changes in high sensitive C reactive protein (CRP) levels. | 6 weeks | Secondary end points included any change of non-LDL-cholesterol, total cholesterol, high-density lipoprotein (HDL), very-low-density lipoprotein (VLDL), triglycerides levels, and changes in high sensitive C reactive protein (CRP) levels from baseline up to 6 week treatment. |
Countries
Brazil
Outcome results
None listed